Ramachandran Niro Ph.D 4
4 · Akoya Biosciences, Inc. · Filed Feb 17, 2023
Insider Transaction Report
Form 4
Ramachandran Niro Ph.D
Chief Business Officer
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-02-15−34,000→ 62,566 totalExercise: $0.91Exp: 2030-03-23→ Common Stock (34,000 underlying) - Exercise/Conversion
Common Stock
2023-02-15$0.91/sh+34,000$30,940→ 156,680 total
Footnotes (1)
- [F1]The option vested as follows: one-fourth (1/4) of the shares on July 13, 2021 and the remaining shares shall vest in 36 equal monthly installments beginning on July 13, 2021, until fully vested, subject to reporting person's continuous employment.